<DOC>
	<DOCNO>NCT00023387</DOCNO>
	<brief_summary>Primary objective : To compare pharmacokinetics rifapentine 25-desacetyl rifapentine three different dos : 600 mg , 900 mg , 1200 mg . Secondary objective : To describe correlation pharmacokinetic parameter three different dos rifapentine plus standard dose isoniazid occurrence toxicity attribute anti-tuberculosis treatment .</brief_summary>
	<brief_title>TBTC Study 25PK : Intensive Pharmacokinetic Study Three Doses Rifapentine 25-Desacetyl Rifapentine</brief_title>
	<detailed_description>We enroll 24-36 patient , 8-12 dose 600 , 900 1200 mg rifapentine Admissions pharmacokinetic study take place continuation phase tuberculosis therapy . Patients participate double-blinded trial tolerability safety high dos rifapentine continuation phase therapy consent participate pharmacokinetic study may admit Clinical Research Center ( CRC ) allow frequent blood sample 24-hour period . Otherwise , patient evaluate clinic .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Inclusion : Patients enrol TBTC Study 25 Informed consent Exclusion : Severe anemia ( Hct &lt; 25 % ) Any severe adverse event relate study drug TBTC Study 25</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>